Analysis of T-cell receptor repertoire and immune microenvironment in malignant lymphoma

2023 Fiscal Year Final Research Report

• Project/Area Number: 21K07407
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 52010:General internal medicine-related
• Research Institution: Tokyo Metropolitan Hospital Organization Tokyo Metropolitan Komagome Hospital
• Principal Investigator: Kanemasa Yusuke 地方独立行政法人東京都立病院機構東京都立駒込病院(臨床研究室), 腫瘍内科, 医長 (30868633)
• Co-Investigator(Kenkyū-buntansha): 下山 達 地方独立行政法人東京都立病院機構東京都立駒込病院(臨床研究室), 腫瘍内科, 部長 (70450591) ; 大保木 啓介 公益財団法人東京都医学総合研究所, ゲノム医学研究センター, 副参事研究員 (80415108)
• Project Period (FY): 2021-04-01 – 2024-03-31
• Keywords: 悪性リンパ腫 / 腫瘍免疫微小環境 / T細胞受容体レパトア

Outline of Final Research Achievements

To develop prognostic indicators based on immune profiles, we reanalyzed DLBCL RNA-seq data. patients with low T cell receptor (TCR) diversity had significantly better progression free interval (PFI) than those with high diversity. TCR diversity was associated with CIBERSORT-derived regulatory T-cell (Treg) virtual fraction; the combination of Treg fraction and TCR diversity successfully stratified patients with the shortest PFI. Using a logistic regression model, we selected two final genes and developed a scoring system to explain the Treg fraction. Patients with low scores and high TCR diversity had very short PFI compared to the other combinations.

Free Research Field

腫瘍免疫

Academic Significance and Societal Importance of the Research Achievements

DLBCLにおいて、TCRや腫瘍浸潤免疫細胞種を利用した予後予測法を開発した報告はなく、本研究の新規性は高い。TCRレパトアやTregは、単に予後予測だけでなく、腫瘍免疫のメカニズムの理解や、抗腫瘍免疫反応を増強する新しい治療法の開発にとっても極めて重要な知見となり、近い将来、患者における抗腫瘍免疫の回復法の開発に向けて大きく貢献する可能性を秘めている。